Skip to the beginning of the images gallery

Pembrolizumab Biosimilar - Research Grade

Q: Is the Pembrolizumab biosimilar available in gram quantities?

Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Pembrolizumab biosimilar suitable for in vivo studies?

Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Pembrolizumab biosimilar target?

It is an unconjugated, non-therapeutic biosimilar analog of Pembrolizumab that binds human PD-1; for research use only (RUO).

In stock

Only %1 left

SKU

ICH4029

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Pembrolizumab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

IgG4 kappa

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This is a research-grade, unconjugated recombinant analog of pembrolizumab, an anti-PD-1 antibody, supplied for research use only and not for human or veterinary use. It is a non-therapeutic biosimilar built around the PD-1 (PDCD1) target with a human IgG4 kappa framework, intended to reproduce the binding behavior of the originator molecule for in-vitro and preclinical laboratory work rather than clinical treatment. Researchers use it as a defined, lot-consistent tool for studying PD-1 engagement and PD-1/PD-L1 axis blockade: as a positive control in binding and blocking assays, a reference reagent when benchmarking new anti-PD-1 candidates, a capture or detection tool in immunoassays, and a component in checkpoint-blockade mechanism studies. It is offered as a low-endotoxin preparation (research grade typically <1 EU/mg, ultra-low <0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support assay development, screening, and reproducibility across experiments. Because it is a functional analog of the drug rather than the clinical product, it is intended strictly for research and biosimilarity/characterization applications. PD-1 (Programmed cell death protein 1; gene PDCD1; UniProt Q15116) is a type I transmembrane inhibitory receptor of the CD28/B7 immunoglobulin superfamily, expressed on activated T cells and also on B cells, NK cells, and other immune subsets. Its ectodomain binds two ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2). Ligand engagement clusters PD-1 at the immune synapse and recruits SHP-2 (and SHP-1) phosphatases to its cytoplasmic ITIM and ITSM motifs, dampening TCR and CD28 signaling. This attenuates T-cell proliferation, cytokine production, and cytotoxic activity, serving as a peripheral tolerance checkpoint. Tumors and chronically infected tissues exploit PD-1 signaling to drive T-cell exhaustion, which is why blocking the PD-1/PD-L1 interaction restores effector function and underpins checkpoint-inhibitor immunotherapy.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Pembrolizumab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Faq (q&a)

Q: Is the Pembrolizumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Pembrolizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Pembrolizumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Pembrolizumab that binds human PD-1; for research use only (RUO).

Write Your Own Review

You're reviewing:Pembrolizumab Biosimilar - Research Grade

Your Rating